Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mixed Data For Merck KGaA's Disease-Modifying OA Drug

German firm looking to partner sprifermin

Executive Summary

Sprifermin could be the first drug to affect the underlying disease process in osteoarthritis but data show no significant improvement in symptoms.

You may also be interested in...



Merck KGaA Says New Meds Will Add €2bn Sales

The German group believes its €2bn target of pipeline sales by 2022 is achievable. It is hoping for a healthy contribution from rare lung cancer drug tepotinib.

$140m Cash Boost For Leyden Labs Anti-Flu Nasal Spray

The Dutch biotech has signed off a sizeable series B fundraising to take its intranasal products to fight current and future viral outbreaks into the clinic.

Pharma Heads Hope Trust Built Through Pandemic With Policymakers Will Last

The bosses of Bayer and Roche's pharmaceutical divisions – Stefan Oelrich and Bill Anderson – have called on governments in Europe to create a friendlier environment so that the sector and policymakers can continue to work better together post-pandemic.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125993

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel